Retraction notice to: Silencing EGFR/HER3 signaling with a novel anti-EGFR domain II/IV antibody [Cancer Lett. 357 (2015) 374-383].

Cancer Lett

Translational Medicine Research Institute and International Joint Cancer Institute, The Second Military Medical University, Shanghai 200433, China; Asian-Pacific Biosignatures Center, Tianjin Joint Academy of Biomedicine and Technology, Tianjin 300457, China; Molecular Drug Discovery Center, Xi'an Jinwa Pharmaceutical Co., Ltd, Xi'an, Shaanxi 710000, China. Electronic address:

Published: August 2017

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.canlet.2017.05.014DOI Listing

Publication Analysis

Top Keywords

retraction notice
4
notice silencing
4
silencing egfr/her3
4
egfr/her3 signaling
4
signaling novel
4
novel anti-egfr
4
anti-egfr domain
4
domain ii/iv
4
ii/iv antibody
4
antibody [cancer
4

Similar Publications

This article has been retracted: please see Elsevier Policy on Article Withdrawal (https://www.elsevier.com/about/policies/article-withdrawal).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!